Cargando…
Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway
Autores principales: | Wei, Xuan, Shi, Juanjuan, Lin, Qianhan, Ma, Xiaoxue, Pang, Yingxin, Mao, Hongluan, Li, Rui, Lu, Wei, Wang, Yu, Liu, Peishu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453349/ https://www.ncbi.nlm.nih.gov/pubmed/34557417 http://dx.doi.org/10.3389/fonc.2021.742374 |
Ejemplares similares
-
Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway
por: Wei, Xuan, et al.
Publicado: (2021) -
GABPA Expression in Endometrial Carcinoma: A Prognostic Marker
por: Ma, Xiaoxue, et al.
Publicado: (2021) -
Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer
por: Luan, Wenqing, et al.
Publicado: (2019) -
MiR-519d represses ovarian cancer cell proliferation and enhances cisplatin-mediated cytotoxicity in vitro by targeting XIAP
por: Pang, Yingxin, et al.
Publicado: (2014) -
Overexpression of Nucleolin is a Potential Prognostic Marker in Endometrial Carcinoma
por: Lin, Qianhan, et al.
Publicado: (2021)